1. Home
  2. VRAX vs NXTS Comparison

VRAX vs NXTS Comparison

Compare VRAX & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virax Biolabs Group Limited

VRAX

Virax Biolabs Group Limited

N/A

Current Price

$2.63

Market Cap

2.3M

Sector

Health Care

ML Signal

N/A

Logo Nexentis Technologies Inc. Common Stock

NXTS

Nexentis Technologies Inc. Common Stock

N/A

Current Price

$1.67

Market Cap

2.5M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
VRAX
NXTS
Founded
2013
2009
Country
United Kingdom
Israel
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Agricultural Chemicals
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
2.3M
2.5M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
VRAX
NXTS
Price
$2.63
$1.67
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$1.00
N/A
AVG Volume (30 Days)
481.2K
18.0K
Earning Date
06-12-2026
05-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$263,445.00
Revenue This Year
$217,274.83
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.10
$0.55
52 Week High
$13.19
$23.80

Technical Indicators

Market Signals
Indicator
VRAX
NXTS
Relative Strength Index (RSI) 44.27 37.14
Support Level $2.55 $1.43
Resistance Level $3.10 $2.08
Average True Range (ATR) 0.30 0.15
MACD -0.05 0.03
Stochastic Oscillator 4.55 6.82

Price Performance

Historical Comparison
VRAX
NXTS

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.

About NXTS Nexentis Technologies Inc. Common Stock

Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.

Share on Social Networks: